Abstract
The natural course of hepatitis B virus (HBV) infection is variable, and chronic hepatitis B (CHB) disease exhibits itself through a spectrum of clinical manifestations. These factors contribute to the challenges faced when managing patients who live with HBV infection. Furthermore, conventional treatment options (e.g., interferon alfa-2a, lamivudine, and adefovir) are moderately effective and can be associated with problems, such as poor tolerability (interferon alfa-2a) and the development of drug resistance (lamivudine). Over the last 5 years, several antiviral agents including entecavir, peginterferon alfa-2a, and telbivudine which are more efficacious and have improved tolerability over previous drugs have become available. The availability of novel antiviral agents and advances in understanding resistance patterns of antiviral agents has resulted in refinement of CHB treatment recommendations and guidelines. More recently, evidence from clinical trials suggests the central importance of virologic suppression as an indicator of treatment outcome and the predictive value of on-treatment HBV DNA levels in response to antiviral therapy. This review highlights the goals of therapy and clinical experience with therapies that are newly licensed or in the late stages of clinical development. Current approaches for treating CHB and new strategies for optimizing response to therapy are also discussed.
Similar content being viewed by others
Abbreviations
- ALT:
-
Alanine aminotransferase
- AST:
-
Aspartate aminotransferase
- CHB:
-
Chronic hepatitis B
- HBeAg:
-
Hepatitis B e antigen
- HBsAg:
-
Hepatitis B surface antigen
- HBV:
-
Hepatitis B virus
- HIV:
-
Human immunodeficiency virus
- PCR:
-
Polymerase chain reaction
- PEG:
-
Polyethylene glycol
- NA:
-
Nucleoside or nucleotide analog
- ULN:
-
Upper limit of normal
References
ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26 Suppl 2:47–58.
de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL international consensus conference on hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39 Suppl 1:S3–25.
Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–62.
Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–89.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.
Di Bisceglie A, Lai C-L, Gane E, Chen YC, Thongasawat S, Wang YM, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients [abstract 112]. Hepatology. 2006;44:230A–1A.
Gane E, Lai C-L, Liaw Y-F. Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: efficacy, safety, and predictors of response at 1 year [abstract 493]. J Hepatol. 2006;44:S183–4.
Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40 kD) ± lamivudine: 3-year follow-up results [abstract 53]. J Viral Hepat. 2007;46 Suppl 1:S25–6.
Zeuzem S, Lai CL, Gane E, Liaw YF, Thongsawat S, Wang Y, et al. Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients. J Hepatol. 2006;44 Suppl 2:S24.
Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890–7.
Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173–81.
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–95.
Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–17.
Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56:699–705.
Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005;142:240–50.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet. 2005;365:123–9.
Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Sourfleris K, et al. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol. 2007;22:1582–8.
Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersoz G, et al. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007;51:3020–22.
Hadziyannis S. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–7.
Marcellin P. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–16.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–51.
Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat. 2006;13:250–5.
Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283–90.
Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic hepatitis B patients treated with ADV. Gut. 2006;55:1488–95.
Fung SK, Andreone P, Han SH, Rajender RK, Regev A, Keeffe EB, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol. 2005;43:937–43.
Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs. 2007;16:777–86.
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039–49.
Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81:3992–4001.
Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother. 2007;60:201–5.
Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656–65.
Colonno R, Rose R, Pokornowski K, Baldick CJ, Klesczewski K, Tenney D. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients [abstract 110]. Hepatology. 2006;44:229A–30A.
Colonno R, Rose R, Pokornowski K, Baldick CJ, Eggers B, Yu ES, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients [abstract 781]. Last update: 2007. Available at: http://www.easl.ch/easl2007/Program/session1.asp?SessionId=PS14&SSessionDate=4/14/2007. Accessed October 5, 2007.
Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51:902–11. Epub 2006 Dec 18.
Lai C-L, Gane E, Liaw Y-F, et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the international phase III globe trial [abstract LB1]. Hepatology. 2005;42:748A.
Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–36.
Lai C-L, Gane E, Hsu CW, Thongsawat S, Wang Y, Chen Y, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine [abstract 91]. Hepatology. 2006;44:22A.
van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421–5.
van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44:318–25.
Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385–91.
Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307–13.
Zhu Y, Qi X, Delaney W, Curtis M, Miller MD, Borroto-Esoda K. Anti-HBV activity of in vitro combinations of tenofovir with nucleoside analogs [abstract 172]. Hepatology. 2006;44:253a.
Sung JJY, Lai JY, Zeuzem S, et al. A randomized double-blind phase II study of lamivudine (LAM) compared with lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis [abstract 69]. J Hepatol. 2003;38 Suppl 2:25–6.
Lampertico P, Marzano A, Levrero M, Santantonio T, DiMarco V, Brunetto M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B [abstract LB5]. Hepatology. 2006;44:693A–4A.
Piccolo P, Lenci I, DiPaolo D, Telesca C, DeMelia L, Sorbello O, et al. Peginterferon-alpha-2a plus adefovir vs. peginterferon alpha-2a for 48 weeks in HBeAg-negative chronic hepatitis B: preliminary 24 week results of the Peg for B randomized multicenter trial [abstract 54]. J Hepatol. 2007;46:S26.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chang, TT., Suh, D.J. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2 (Suppl 1), 19–27 (2008). https://doi.org/10.1007/s12072-008-9059-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-008-9059-0